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Background
In Mozambique the reported prevalence of HIV infection in 
the adult population is of 16.1% (12.5% – 20%), equivalent 
to 980,000 to 1,700,000 HIV infected people, of which more 
than  200,0001  are  in  urgent  need  of  antiretroviral 
treatment.
In Mozambique, like in several sub Saharan countries, access 
to ART is still very limited (10.8% of the population in urgent 
need).
To scale up the number of patients on ART, The Ministry of Health 
of Mozambique has launched a policy of decentralisation of 
the comprehensive HIV/AIDS care and treatment to peripheral 
health centres. MSF is supporting the national plan in the Health 
District of Chamanculo in Maputo (with an estimated population 
of 300.000).
At May 2006,  MSFCH provides care to 5.700 HIV positive 
people and ARV therapy to 3.275 of them, in a governmental 
day hospital at district level and using the national guidelines. 
Aware of unmet needs for treatment, MSF has committed to 
accelerate and increase inclusions of patients on ART, but this 
could only go together with the simpliﬁ  cation of the national 
protocols.
In  the  national  treatment  guideline,  the  ﬁ  rst-line  regimen 
contains NVP (unless transaminases (ALT) >5x ULN) or EFV 
for patients in treatment for tuberculosis. 
In case of severe hepatic toxicity, deﬁ  ned as an increase of ALT 
> 5 x ULN during the course of therapy, ART is interrupted and 
NVP replaced by EFV.
The guideline strongly recommends a regular transaminases 
assessment before and during the treatment; therefore ALT 
is checked for all patients eligible for ART at baseline, two 
weeks after initiation, 1 month and then six monthly, unless 
abnormalities are encountered. 
Performing ALT is very demanding in terms of logistics and 
costs in resource-poor settings and could be an obstacle to the 
scaling up policy foreseen by the Ministry of Health and other 
health partners.
We decided to assess the results in term of  impact on patient 
management and therefore pertinence from a public health 
perspective  of  regularly  performing  ALT,  by  a  retrospective 
analysis of the cohort followed in the day hospital of Alto Mae, 
District of Chamanculo and on the ﬁ  les of 19 patients for which 
ART were interrupted because of hepatotoxicity. 
Methods
In  MSF  service,  the  patients’  ﬁ  les  are  regularly  updated 
during medical visits and all the data of clinical follow-up are 
systematically collected using a monitoring software (Fuchia©, 
Epicentre, Paris, France) that provides automated reports and 
allows for speciﬁ  c analysis.
Using data routinely collected through Fuchia, we conducted a 
small retrospective study based on patients’ ﬁ  les. 
From the cohort of patients who started ART any time from 
March 2003 to December 2005, we selected all the ﬁ  les of the 
patients who developed any intolerance that necessitated ART 
interruption  and  we  focused  our  analysis  on  those  who  presented 
with elevated transaminase values (normal values11-45 U/l 
for males and 11-35 U/l for females) justifying a change in the 
treatment regimen.
For    the  19  patients  who  interrupted  ART  because  of 
hepatotoxicity,  the  following  variables  were  analysed:  age, 
sex, clinical and immunological situation at baseline, date of 
start of ART, baseline ALT, all available values of ALT (after two 
weeks of treatment - 1 month - 3 months, etc), date of ART 
interruption, clinical signs at the time of interruption, date of 
the restart of the alternative treatment.
This information was taken from the patient’s ﬁ  les, entered in 
Epi info software and simple descriptive analysis was done.
Results
In the Day Hospital of Alto Mae, 3.146 patients started ART 
from March 2003 to December 2005, 2.367 (75%) were still 
on treatment at the end of the period, with a median follow 
up of around 12 (IQR: 7-16) months. In the ART cohort, 157 
(5%) patients died, 141 (4.5%) had to stop treatment for any 
reason and 540 (17.1%) were lost to follow up or with missing 
data.
Out  of  the  3.146  patients  followed  from  March  2003  to 
December 2005, 90% were on standard ﬁ  rst line D4T/3TC/
NVP; the remaining had to shift to another regimen due to 
contraindications or concomitant tuberculosis.
Of the 141 people who had to stop treatment, the causes were 
reported for 127 of them:
•  4 (2.8%) for neuropathy, 
•  19 (13.4%) for hepatotoxicity, 
•  45 (32%) for skin reactions,
•  59 (41.8%) for other allergic reactions
19 cases of drug interruption due to liver toxicity were found, 
giving a global incidence of 0.6% (0.9% if calculated on patients 
still  in  follow  up).  All  these  patients,  except  one  were  on 
treatment with a NVP based regimen (1 case on EFV because 
of concomitant TB)
There were equally male and female in this group of patients.
The median  age was 39 (range 25 – 65). 
At ART initiation, the distribution of the 19 patients concerning 
WHO clinical stages was similar to that of the global cohort:
•  1 (5%) in stage 1
•  3 (16%) in stage 2
•  10 (53%)in stage 3
•  5 (26%) in stage 4. 
The average Cd4 count was of 91 cell/mm3 (13-280).
As far as ALT values are concerned:
•  For the patients who developed severe hepatotoxicity, the 
median ALT value at the time of ARV initiation was  37.0 
(14.0 – 129.0) U/L
•  The highest median value of ALT measured after initiation 
of ART was at 1 month-follow up, and was 308 (0.0-897.0) 
U/L. 
•  The median of ALT at interruption of ART was 376.0 (155.0-
897.0) U/L.
•  The average increase of ALT, from initiation to the date of 
ART interruption, was 415.8 (126.0-877.0) U/L.
•  The median of ALT at the time of shift to the alternative 
treatment was 55.0 (15.0-235.0) U/L.
As far as the time of interruption is concerned, 52.6% of 
patients interrupted at 1 month-follow up, cumulatively, 74% 
of patients had interrupted at 2 months-follow up.
As far as clinical symptoms and signs are concerned:
Thirteen (68.4%) patients who interrupted ART treatment did 
not  have  any  clinical  symptom  and  sign  at  the  moment  of 
interruption. There were no differences in the baseline median 
Cd4 values between symptomatic and asymptomatic patients 
(65 and 99 respectively).
The different clinical signs and symptoms equally presented 
were:  asthenia,  jaundice,  abdominal  pain,  liver  pain  and 
hepatomegaly.
Conclusions
Despite the small number of patients, our study can give an orientation on the pertinence of the regular 
monitoring of transaminases for patients on ART.
 
Only 19 (0.6%) of 3.146 patients who started ART developed severe liver toxicity justifying changes in 
regimen.
This retrospective study has many limitations: data are routinely collected and do not allow for the analysis 
of possible other causes of liver problems (eg: co infection with viral hepatitis), patients that are lost to 
follow up or dead can also have had liver impairment, causing an underreporting of the toxicity.
 
Our data conﬁ  rm the increased risk of toxicity in the ﬁ  rst 2 months of treatment; an increased surveillance 
is therefore necessary during this period.
More than half of the patients with severe liver toxicity were asymptomatic. It is therefore important to 
investigate (through bigger and ad hoc studies) risk factors and mild symptoms suggestive of liver toxicity 
to deﬁ  ne new algorithms for the management of hepatic side effects and better target the use of resources 
in the monitoring of ART toxicity. 
Besides speciﬁ  c patients (pregnant women, TB patients or patients symptomatic for liver dysfunction), the 
pertinence in terms of cost/efﬁ  cacy of regular ALT tests should be questioned. Simpliﬁ  cation of protocols 
will facilitate follow up of patients on ART in peripheral health structures in resources-poor settings.
(Footnotes)
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